News

These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide

Covagen’s lead product COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is currently in a Phase Ib trial for psoriasis. COVA 322 is also said to

In October 2013, Zorvolex was approved by the FDA to treat mild to moderate acute pain in adults. The prescription-based Zorvolex is the first FDA-approved low dose NSAID

About 25% and possibly up to 50% of deceased-donor kidney transplant cases are affected by DGF, an early and serious complication of organ transplantation. DGF is characterized by

Triumeq is the company’s first dolutegravir-based fixed-dose combination (FDC) which provides HIV patients the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir,

A decision from the European Commission (EC) regarding the approval of ceftolozane/tazobactam is expected during the second half of 2015 The marketing application is based on positive data

The company’s ANDA product is a generic version of UCB’s Neupro, which is designed to treat signs and symptoms of idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs

The company has also secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product. The product is

Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware (Case No. 1:14-cv-01088